Cancer immunotherapy by immune checkpoint blockade has proven its great potential by
saving the lives of a proportion of late stage patients with immunogenic tumor types …

Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is
notoriously resistant to immunotherapy mainly due to its unique immune microenvironment …

The limited efficacy of immunotherapies against glioblastoma underscores the urgency of
better understanding immunity in the central nervous system. We found that treatment with …

Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is
associated with a poor clinical prognosis. Despite the progress in the understanding of the …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

The characteristics of the primary tumor blood vessels and the tumor microenvironment drive
the enhanced permeability and retention (EPR) effect, which confers an advantage towards …

The use of immunotherapies for the treatment of brain tumors is a topic that has garnered
considerable excitement in recent years. Discoveries such as the presence of a glymphatic …

Glioblastoma is one of the most common and detrimental forms of solid brain tumor, with
over 10,000 new cases reported every year in the United States. Despite aggressive …

Simple Summary This paper summarizes the crosstalk between tumor/non-tumor cells and
other elements of the glioblastoma (GB) microenvironment. In tumor pathology, glial cells …

Gliomas are one of the most lethal types of cancers accounting for∼ 80% of all central
nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the …